Related references
Note: Only part of the references are listed.FOLFOXIRI reintroduction in metastatic colorectal cancer
Rob Glynne-Jones et al.
LANCET ONCOLOGY (2020)
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini et al.
LANCET ONCOLOGY (2020)
Effectiveness of guideline dissemination and implementation strategies on health care professionals' behaviour and patient outcomes in the cancer care context: a systematic review
Jennifer R. Tomasone et al.
IMPLEMENTATION SCIENCE (2020)
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
Chiara Cremolini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Nationwide Flash-Mob Study for Suspected Acute Coronary Syndrome
Angel M. R. Schols et al.
ANNALS OF FAMILY MEDICINE (2019)
A HaemSTAR-led, UK-wide ‘flash-mob’ audit of intravenous immunoglobulin use in immune thrombocytopenia
Phillip Nicolson et al.
CLINICAL MEDICINE (2019)
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
Kaitlyn K. H. Goey et al.
EUROPEAN JOURNAL OF CANCER (2018)
Quality and Quantity of Sleep and Factors Associated With Sleep Disturbance in Hospitalized Patients
Hilde M. Wesselius et al.
JAMA INTERNAL MEDICINE (2018)
Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
The Power of Flash Mob Research Conducting a Nationwide Observational Clinical Study on Capillary Refill Time in a Single Day
Jelmer Alsma et al.
CHEST (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Flash Mob Research A Single-Day, Multicenter, Resident-Directed Study of Respiratory Rate
Matthew W. Semler et al.
CHEST (2013)
The answer is 17 years, what is the question: understanding time lags in translational research
Zoe Slote Morris et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2011)
Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases
L. J. M. Mekenkamp et al.
BRITISH JOURNAL OF CANCER (2010)
Diffusion Theory and Knowledge Dissemination, Utilization, and Integration in Public Health
Lawrence W. Green et al.
ANNUAL REVIEW OF PUBLIC HEALTH (2009)
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
Erik von Elm et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2007)
Evaluating payback on biomedical research from papers cited in clinical guidelines: applied bibliometric study
J Grant et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
